Kedrion Biopharma is prospected by companies that are selling Diversity, Privacy, Market Intelligence, Supply chain, Live events, Procurement and other solutions. Explore these insights to prepare for your prospecting with Kedrion Biopharma.
Start a Free Trial for Kedrion Biopharma + 9 other target accounts
Kedrion’s global portfolio expands to China
(source: https://www.kedrion.com/kedrions-global-portfolio-expands-to-china/)
Intel type: Deals & Partnerships
Date: 26 June 2023
Kedrion Biopharma has announced that China’s National Institutes for Food and Drug Control (NIFDC) has approved BPL’s human Albumin product for release to the Chinese market. BPL is part of Kedrion since 2022. As the first ever approval for a BPL product in China, this is a major milestone for our whole company, which from now can ship to the country on a regular basis. China is by far the largest human Albumin market in the world of 627 tons vs global demand of 1,368 tons in 2021 .
“We are delighted to be able to provide this product to patients in China,” said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. “Obtaining this important license and full distribution agreement in China reflects strongly on our current plan for global expansion while highlighting our corporate mission of providing plasma-derived products worldwide, supporting both healthcare professionals and patients every day.”
Zhou Xianfeng, Chairman of Board, Hangzhou Jiansheng Medicine Co. Ltd. said, “We are delighted to have partnered with BPL and Kedrion, which are truly committed to making therapies available in all parts of the world by expanding into important new markets such as China.”
This insight is useful for your prospecting if your business deals with: Supply chain, Procurement, Security, Compliance, Finance, Transport and Contract management services
Is Kedrion Biopharma a target account for you? Get insights about Kedrion Biopharma and 9 more accounts relevant to YOUR business, from B2Brain – set up your 14 day Free Trial from here.
Kedrion strengthens its network of plasma collection centers
(source: https://www.kedrion.com/kedrion-strengthens-its-network-of-plasma-collection-centers/)
Intel type: Stores & Locations
Date: 05 Dec 2022
Kedrion has announced the acquisition of Czech companies UNICAplasma s.r.o and UNICAplasma Morava s.r.o., which operate five plasma collection centers in the Czech Republic.
The centres, which have an annual collection capacity of approximately 70,000 liters and employ 83 people, are managed throughout the entire territory of the Czech Republic under two different brands: UNICAplasma in Prague and Mojeplazma in Kladno, Ostrava, Frýdek-Místek and Český Těšín.
«We believe that this acquisition will greatly enhance the value of our company – stated Paolo Marcucci, Kedrion Chairman and CEO – allowing us to become a player in the collection of plasma in Europe. Through this operation we will be able to secure an increasing amount of high quality plasma for our production plants, this unique and special raw material for the production of crucial plasma-derived products to prevent and treat rare and debilitating conditions».
«We are very proud to add these new companies to the Kedrion group – added Paolo Marcucci – and we welcome all new employees into our corporate family. A special welcome also goes to donors: their contribution is vital in helping to provide life-improving and life-saving therapies to the growing number of patients that we serve around the world».
The centers will continue to be managed by Milan Maly, one of the pioneers in the industry in the Czech Republic (the center in Prague began operations in 2008). Mr. Maly is also the founder and the chairperson of the Czech Association of Plasma and chairman of the European Plasma Alliance (EPA), the European plasma collectors association.
This insight is useful for your prospecting if your business deals with: Security, Healthcare, Contract management, Supply chain, Procurement services
Is Kedrion Biopharma a target account for you? Get insights about Kedrion Biopharma and 9 more accounts relevant to YOUR business, from B2Brain – set up your 14 day Free Trial from here.
Kedrion awarded national tender for Portuguese plasma manufacturing
(source: https://www.kedrion.com/kedrion-awarded-national-tender-for-portuguese-plasma-manufacturing/)
Intel type: Deals & Partnerships
Date: 02 March 2022
Kedrion’s global commitment to improving the living conditions of people suffering from rare diseases also runs through our partnerships with communities and health systems around the world that strive for national self-sufficiency in plasma-derived therapies.
The latest addition to our international contract manufacturing pipeline is Portugal, where a national tender for manufacturing plasma into medicines was awarded to Kedrion in late 2022.
The first shipments of Portuguese plasma coming from the blood centers in Porto and Lisbon occurred on January 31st and February 1st, respectively, with more shipments scheduled from Lisbon, Coimbra, and Porto through the end of 2023.
This insight is useful for your prospecting if your business deals with: Supply chain, Procurement, Security, Compliance, Finance, Transport and Contract management services
Have you read these?
Is Kedrion Biopharma a target account for you? Get insights about Kedrion Biopharma and 9 more accounts relevant to YOUR business, from B2Brain – set up your 14 day Free Trial from here.
